Answer
The most commonly reported adverse reactions to oritavancin diphosphate are nausea, hypersensitivity reactions, infusion site reactions and headache.
Sources for this answer
- Tenkasi 400 mg powder for concentrate for solution for infusionA. Menarini Farmaceutica Internazionale SRL · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked